Megatherapy combining I131 metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma

M. Miano, A. Garaventa, M. R. Pizzitola, M. S Lo Piccolo, S. Dallorso, G. P. Villavecchia, C. Bertolazzi, M. Cabria, B. De Bernardi

Research output: Contribution to journalArticle

Abstract

Despite the use of aggressive chemotherapy, stage 4 high risk neuroblastoma still has very poor prognosis which is estimated at 25%. Metabolic radiotherapy with I131 MIBG appears a feasible option to enhance the effects of chemotherapy. Seventeen patients having MIBG-positive residual disease received 4.1-11.1 mCi/kg of I131 MIBG 7-10 days before initiating the high-dose chemotherapy cycle consisting of busulphan 16 mg/kg and melphalan 140 mg/m2 followed by PBSC infusion. We compared the toxicity in these patients to that seen in 15 control subjects with neuroblastoma who underwent a PBSC transplant without MIBG therapy. We observed greater toxic involvement of the gastrointestinal system in children treated with I131 MIBG: grade 2 or 3 mucositis developed in 13/17 patients treated with I131 MIBG and in 9/15 treated without it. Grade 1-2 gastrointestinal toxicity occurred in 12/17 children given MIBG and in 5/15 of the controls. One child receiving I131 MIBG developed transient interstitial pneumonia. Another child who also received I131 MIBG after PBSC rescue developed fatal pneumonia after the third course of metabolic radiotherapy. Our experience indicates that MIBG can be included in the high-dose chemotherapy regimens followed by PBSC rescue for children with residual neuroblastoma taking up MIBG. Attention should be paid to avoiding lung complications. Prospective studies are needed to demonstrate the real efficacy of this treatment.

Original languageEnglish
Pages (from-to)571-574
Number of pages4
JournalBone Marrow Transplantation
Volume27
Issue number6
DOIs
Publication statusPublished - 2001

Fingerprint

3-Iodobenzylguanidine
Hematopoietic Stem Cells
Neuroblastoma
Drug Therapy
Radiotherapy
Busulfan
Mucositis
Melphalan
Poisons
Interstitial Lung Diseases
Pneumonia

Keywords

  • I-metaiodobenzylguanidine
  • Neuroblastoma
  • Peripheral blood stem cell transplantation
  • Toxicity

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Megatherapy combining I131 metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. / Miano, M.; Garaventa, A.; Pizzitola, M. R.; Piccolo, M. S Lo; Dallorso, S.; Villavecchia, G. P.; Bertolazzi, C.; Cabria, M.; De Bernardi, B.

In: Bone Marrow Transplantation, Vol. 27, No. 6, 2001, p. 571-574.

Research output: Contribution to journalArticle

Miano, M. ; Garaventa, A. ; Pizzitola, M. R. ; Piccolo, M. S Lo ; Dallorso, S. ; Villavecchia, G. P. ; Bertolazzi, C. ; Cabria, M. ; De Bernardi, B. / Megatherapy combining I131 metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. In: Bone Marrow Transplantation. 2001 ; Vol. 27, No. 6. pp. 571-574.
@article{68b640cbe8ce4040a901eca2b5f2e4ee,
title = "Megatherapy combining I131 metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma",
abstract = "Despite the use of aggressive chemotherapy, stage 4 high risk neuroblastoma still has very poor prognosis which is estimated at 25{\%}. Metabolic radiotherapy with I131 MIBG appears a feasible option to enhance the effects of chemotherapy. Seventeen patients having MIBG-positive residual disease received 4.1-11.1 mCi/kg of I131 MIBG 7-10 days before initiating the high-dose chemotherapy cycle consisting of busulphan 16 mg/kg and melphalan 140 mg/m2 followed by PBSC infusion. We compared the toxicity in these patients to that seen in 15 control subjects with neuroblastoma who underwent a PBSC transplant without MIBG therapy. We observed greater toxic involvement of the gastrointestinal system in children treated with I131 MIBG: grade 2 or 3 mucositis developed in 13/17 patients treated with I131 MIBG and in 9/15 treated without it. Grade 1-2 gastrointestinal toxicity occurred in 12/17 children given MIBG and in 5/15 of the controls. One child receiving I131 MIBG developed transient interstitial pneumonia. Another child who also received I131 MIBG after PBSC rescue developed fatal pneumonia after the third course of metabolic radiotherapy. Our experience indicates that MIBG can be included in the high-dose chemotherapy regimens followed by PBSC rescue for children with residual neuroblastoma taking up MIBG. Attention should be paid to avoiding lung complications. Prospective studies are needed to demonstrate the real efficacy of this treatment.",
keywords = "I-metaiodobenzylguanidine, Neuroblastoma, Peripheral blood stem cell transplantation, Toxicity",
author = "M. Miano and A. Garaventa and Pizzitola, {M. R.} and Piccolo, {M. S Lo} and S. Dallorso and Villavecchia, {G. P.} and C. Bertolazzi and M. Cabria and {De Bernardi}, B.",
year = "2001",
doi = "10.1038/sj.bmt.1702846",
language = "English",
volume = "27",
pages = "571--574",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Megatherapy combining I131 metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma

AU - Miano, M.

AU - Garaventa, A.

AU - Pizzitola, M. R.

AU - Piccolo, M. S Lo

AU - Dallorso, S.

AU - Villavecchia, G. P.

AU - Bertolazzi, C.

AU - Cabria, M.

AU - De Bernardi, B.

PY - 2001

Y1 - 2001

N2 - Despite the use of aggressive chemotherapy, stage 4 high risk neuroblastoma still has very poor prognosis which is estimated at 25%. Metabolic radiotherapy with I131 MIBG appears a feasible option to enhance the effects of chemotherapy. Seventeen patients having MIBG-positive residual disease received 4.1-11.1 mCi/kg of I131 MIBG 7-10 days before initiating the high-dose chemotherapy cycle consisting of busulphan 16 mg/kg and melphalan 140 mg/m2 followed by PBSC infusion. We compared the toxicity in these patients to that seen in 15 control subjects with neuroblastoma who underwent a PBSC transplant without MIBG therapy. We observed greater toxic involvement of the gastrointestinal system in children treated with I131 MIBG: grade 2 or 3 mucositis developed in 13/17 patients treated with I131 MIBG and in 9/15 treated without it. Grade 1-2 gastrointestinal toxicity occurred in 12/17 children given MIBG and in 5/15 of the controls. One child receiving I131 MIBG developed transient interstitial pneumonia. Another child who also received I131 MIBG after PBSC rescue developed fatal pneumonia after the third course of metabolic radiotherapy. Our experience indicates that MIBG can be included in the high-dose chemotherapy regimens followed by PBSC rescue for children with residual neuroblastoma taking up MIBG. Attention should be paid to avoiding lung complications. Prospective studies are needed to demonstrate the real efficacy of this treatment.

AB - Despite the use of aggressive chemotherapy, stage 4 high risk neuroblastoma still has very poor prognosis which is estimated at 25%. Metabolic radiotherapy with I131 MIBG appears a feasible option to enhance the effects of chemotherapy. Seventeen patients having MIBG-positive residual disease received 4.1-11.1 mCi/kg of I131 MIBG 7-10 days before initiating the high-dose chemotherapy cycle consisting of busulphan 16 mg/kg and melphalan 140 mg/m2 followed by PBSC infusion. We compared the toxicity in these patients to that seen in 15 control subjects with neuroblastoma who underwent a PBSC transplant without MIBG therapy. We observed greater toxic involvement of the gastrointestinal system in children treated with I131 MIBG: grade 2 or 3 mucositis developed in 13/17 patients treated with I131 MIBG and in 9/15 treated without it. Grade 1-2 gastrointestinal toxicity occurred in 12/17 children given MIBG and in 5/15 of the controls. One child receiving I131 MIBG developed transient interstitial pneumonia. Another child who also received I131 MIBG after PBSC rescue developed fatal pneumonia after the third course of metabolic radiotherapy. Our experience indicates that MIBG can be included in the high-dose chemotherapy regimens followed by PBSC rescue for children with residual neuroblastoma taking up MIBG. Attention should be paid to avoiding lung complications. Prospective studies are needed to demonstrate the real efficacy of this treatment.

KW - I-metaiodobenzylguanidine

KW - Neuroblastoma

KW - Peripheral blood stem cell transplantation

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=0035029394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035029394&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1702846

DO - 10.1038/sj.bmt.1702846

M3 - Article

C2 - 11319584

AN - SCOPUS:0035029394

VL - 27

SP - 571

EP - 574

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -